HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

Heart Failure Society of America

The Heart Failure Society of America annual scientific meeting features the latest in management and late-breaking clinical data related to heart failure.

8-in-10 Medicare Beneficiares Hospitalized with HFpEF Could be Considered Candidates for Dapagliflozin

October 04, 2022

An analysis applying data from the DELIVER trial to the Get With The Guidelines-Heart Failure Registry suggests 81% of hospitalized Medicare beneficiaries with HFpEF could be considered candidates for dapagliflozin use under a potential FDA label expansion.

Dapagliflozin's Benefit in HFpEF Reaches Significance Within 2 Weeks, Study Finds

October 03, 2022

A prespecified analysis of the DELIVER trial presented at HFSA 2022 indicates dapagliflozin provides early benefit in patients with heart failure with preserved ejection fraction, with the effect on the trial's primary end point evident in just 13 days.

Sacubitril/Valsartan Use Could Reduce Mitral Regurgitation in HFrEF

October 03, 2022

An analysis of data from the PROVE-HF trial suggests use of sacubitril/valsartan was associated with a reduction in prevalence of mitral regurgitation among patients with heart failure with reduced ejection fraction.

Sotagliflozin Reduces Risk of Recurrent Heart Failure Events

October 02, 2022

New sotagliflozin data at HFSA 2022 provides insight into the apparent reduction in recurrent heart failure events achieved in the SOLOIST-WHF trial. Deepak Bhatt, MD, MPH, provides perspective on the potential role of the dual SGLT1/2 inhibitor, based on trial data, if approved by the US Food and Drug Administration.